Supplementary Figure 5: Stability analyses of WT pertuzumab and SG, YS mutants (as full-length human IgG1/κ antibodies). | Nature Biotechnology

Supplementary Figure 5: Stability analyses of WT pertuzumab and SG, YS mutants (as full-length human IgG1/κ antibodies).

From: Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy

Supplementary Figure 5

(a) WT pertuzumab or SG, YS mutants were stored at 4 °C for 0 days, 4 °C for 30 days, or 37 °C for 5 days and analyzed using size exclusion chromatography. (b) WT pertuzumab or SG, YS mutants were incubated in IgG-depleted, human serum for 0, 3, or 5 days at 37 °C. Antibodies were immunoprecipitated and analyzed by immunoblotting (serum indicates control sample without antibody added). Sizes of molecular weight markers (in kDa) are shown on the left margin. Two independent experiments were carried out with similar results.

Back to article page